{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:12:18Z","timestamp":1792289538422,"version":"4.4.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,23]]},"DOI":"10.1097\/01.aids.0000432445.07437.07","type":"journal-article","created":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T12:32:14Z","timestamp":1373459534000},"page":"2615-2622","source":"Crossref","is-referenced-by-count":14,"title":["Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993\u20132008"],"prefix":"10.1097","volume":"27","author":[{"given":"Lisa M.","family":"Prach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pascopella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pennan M.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Flood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis C.","family":"Porco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Z.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210130","first-page":"423","article-title":"Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.","volume":"133","author":"Mitchison","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"R2-13-20210130","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1001\/jama.283.19.2537","article-title":"Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.","volume":"283","author":"Espinal","year":"2000","journal-title":"JAMA"},{"key":"R3-13-20210130","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1086\/588822","article-title":"The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrug-resistant variants in an HIV-seropositive population.","volume":"198","author":"Bifani","year":"2008","journal-title":"J Infect Dis"},{"key":"R4-13-20210130","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1128\/AM.20.5.810-814.1970","article-title":"Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.","volume":"20","author":"David","year":"1970","journal-title":"Appl Microbiol"},{"key":"R7-13-20210130","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1164\/ajrccm.157.6.9712009","article-title":"Risk factors for rifampin mono-resistant tuberculosis.","volume":"157","author":"Ridzon","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"R8-13-20210130","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"R9-13-20210130","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1086\/516146","article-title":"Rifampin-monoresistant tuberculosis in New York City, 1993-1994.","volume":"25","author":"Munsiff","year":"1997","journal-title":"Clin Infect Dis"},{"key":"R10-13-20210130","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1164\/ajrccm.159.2.9805097","article-title":"Risk factors for rifampin-monoresistant tuberculosis: a case-control study.","volume":"159","author":"Sandman","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"R11-13-20210130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5588\/ijtld.11.0116","article-title":"Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.","volume":"16","author":"Mukinda","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R12-13-20210130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5588\/ijtld.11.0360","article-title":"Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.","volume":"16","author":"Dramowski","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R14-13-20210130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1460458210380524","article-title":"Matching AIDS and tuberculosis registry data to identify AIDStuberculosis comorbidity cases in California.","volume":"17","author":"Xia","year":"2011","journal-title":"Health Inform J"},{"key":"R16-13-20210130","doi-asserted-by":"crossref","first-page":"e26541","DOI":"10.1371\/journal.pone.0026541","article-title":"When tuberculosis comes back: who develops recurrent tuberculosis in California.","volume":"6","author":"Pascopella","year":"2011","journal-title":"PLoS One"},{"key":"R17-13-20210130","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/OLQ.0b013e31821a0635","article-title":"Human immunodeficiency virus testing behaviors among US adults: the roles of individual factors, legislative status, and public health resources.","volume":"38","author":"Du","year":"2011","journal-title":"Sex Transm Dis"},{"key":"R18-13-20210130","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/jama.1995.03530120037038","article-title":"Eleven years of community-based directly observed therapy for tuberculosis.","volume":"274","author":"Chaulk","year":"1995","journal-title":"JAMA"},{"key":"R19-13-20210130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic SocietyCenters for Disease Control and PreventionInfectious Diseases Society of America: treatment of tuberculosis.","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R21-13-20210130","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1164\/rccm.200503-417OC","article-title":"Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.","volume":"173","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R22-13-20210130","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"R23-13-20210130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/JCM.05092-11","article-title":"The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampinrifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.","volume":"50","author":"Tan","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R24-13-20210130","doi-asserted-by":"crossref","first-page":"990","DOI":"10.5588\/ijtld.10.0127","article-title":"Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge.","volume":"15","author":"van Ingen","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"R26-13-20210130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.200903-0439OC","article-title":"Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.","volume":"181","author":"Swaminathan","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-13-20210130","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R28-13-20210130","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R29-13-20210130","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1128\/AAC.48.11.4473-4475.2004","article-title":"Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.","volume":"48","author":"Gurumurthy","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-13-20210130","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1126\/science.1124410","article-title":"The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.","volume":"312","author":"Gagneux","year":"2006","journal-title":"Science"},{"key":"R31-13-20210130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng.1038","article-title":"Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes.","volume":"44","author":"Comas","year":"2012","journal-title":"Nat Genet"},{"key":"R32-13-20210130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1183\/09031936.00157212","article-title":"Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert(R)MTBRIF.","volume":"42","author":"Weyer","year":"2013","journal-title":"Eur Respir J"},{"key":"R33-13-20210130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5588\/ijtld.11.0395","article-title":"False-positive rifampicin resistance on Xpert(R) MTBRIF: case report and clinical implications.","volume":"16","author":"Van Rie","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R34-13-20210130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5588\/ijtld.11.0445","article-title":"Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis.","volume":"16","author":"Smith","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"R35-13-20210130","first-page":"1550","article-title":"HIV testing and diagnosis among adults - United States, 2001-2009.","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.aids.0000432445.07437.07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:46:39Z","timestamp":1620935199000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201310230-00013"}},"subtitle":["a retrospective cohort study"],"short-title":[],"issued":{"date-parts":[[2013,10,23]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/01.aids.0000432445.07437.07","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,23]]}}}